Evidence map›Paper›PMID 33466313›Full record

ArticleMicroorganisms2021

Inhibition of Type III Interferon Expression in Intestinal Epithelial Cells-A Strategy Used by Coxsackie B Virus to Evade the Host's Innate Immune Response at the Primary Site of Infection?

Virginia M Stone, Emma E Ringqvist, Pär G Larsson, Erna Domsgen, Ulrika Holmlund, Eva Sverremark-Ekström, Malin Flodström-Tullberg

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Virginia M StoneCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.
Emma E RingqvistCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0001-6303-6076
Pär G LarssonCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.
Erna DomsgenCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.
Ulrika HolmlundDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.
Eva Sverremark-EkströmDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.
Malin Flodström-TullbergCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0003-2685-2052
Karolinska Institutet · SEKarolinska University Hospital · SEStockholm University · SE

Funding

FP7 Health 260441/PEVNET
6 · The paper itself

Abstract

Increasing evidence highlights the importance of the antiviral activities of the type III interferons (IFNλs; IL-28A, IL-28B, IL29, and IFNλ4) in the intestine. However, many viruses have developed strategies to counteract these defense mechanisms by preventing the production of IFNs. Here we use infection models, a clinical virus isolate, and several molecular biology techniques to demonstrate that both type I and III IFNs induce an antiviral state and attenuate Coxsackievirus group B (CVB) replication in human intestinal epithelial cells (IECs). While treatment of IECs with a viral mimic (poly (I:C)) induced a robust expression of both type I and III IFNs, no such up-regulation was observed after CVB infection. The blunted IFN response was paralleled by a reduction in the abundance of proteins involved in the induction of interferon gene transcription, including TIR-domain-containing adapter-inducing interferon-β (TRIF), mitochondrial antiviral-signaling protein (MAVS), and the global protein translation initiator eukaryotic translation initiation factor 4G (eIF4G). Taken together, this study highlights a potent anti-Coxsackieviral effect of both type I and III IFNs in cells located at the primary site of infection. Furthermore, we show for the first time that the production of type I and III IFNs in IECs is blocked by CVBs. These findings suggest that CVBs evade the host immune response in order to successfully infect the intestine.

Indexed as

Coxsackievirus (CVB)enterovirusIFIH1immune evasioninnate immunityinterferonintestinal epithelial cellsintestinepoly I:Ctype 1 diabetes

Identifiers

PMID33466313
PMCPMC7824802
OpenAlexW3119378713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.